• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IRBs Need Clear Guidance on Restricting Trials’ Use of Data, SACHRP Says

IRBs Need Clear Guidance on Restricting Trials’ Use of Data, SACHRP Says

March 29, 2021

Regulators should issue guidance clarifying that IRBs have the power to restrict trials’ and investigators’ use of certain data and set criteria for such data restrictions, says the Secretary’s Advisory Committee on Human Research Protections (SACHRP).

In a unanimous vote at its triannual meeting last week, SACHRP approved four recommendations, starting with a call for the FDA and HHS’s Office for Human Research Protections (OHRP) to issue guidance explaining that the authority IRBs have to suspend or terminate a study extends to the use of data collected in violation of the Common Rule and equivalent FDA regulations.

The committee’s second recommendation focused on developing clear criteria for judging violations. Some examples of violations include data collected without proper consent, using or publishing data that would likely cause direct harm to trial participants, or when the integrity of data has been compromised by researchers failing to adhere to regulatory and ethical standards.

IRBs want to know where their authority applies and how far they can go with enforcement.

“The purpose [of the recommendation] is to send a message to investigators and other researchers going forward that if they don’t follow the requirements for ethics review, for protocols and with all the regulations, that there are consequences,” said David Forster, WCG chief compliance officer and co-chair of SACHRP’s subcommittee on harmonization.

In its third recommendation, SACHRP said institutions and IRBs should consider, in advance, whether they plan to wield authority to restrict the use of data. If they do, their policies should be written and made publicly available. The fourth recommendation calls for a system of weighing the nature and magnitude of violations to determine how severe enforcement actions should be.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing